Damora Therapeutics (NASDAQ: DMRA) announced inducement equity grants tied to recent hires and its new President and CEO, Jennifer Jarrett, on March 24 and March 30, 2026. The company granted non-qualified options totaling 74,000 shares to four non-executive hires at $23.05, with a 10-year term.
Ms. Jarrett received 500,000 RSUs and non-qualified options to purchase 1,500,000 shares at an exercise price of $25.50. Options vest 25% after one year, then monthly over 36 months; RSUs vest annually over four years. Grants were approved under Nasdaq Listing Rule 5635(c)(4) and subject to Damora's 2022 Inducement Plan and award agreements.
Loading...
Loading translation...
Positive
Appointment of Jennifer Jarrett as President and CEO with 500,000 RSUs and 1,500,000 options
Grants use standard multi-year vesting (25% at one year, then monthly/annual vesting)
Negative
Large option grant of 1,500,000 shares to CEO could create long-term share overhang
Key Figures
Non-executive options:74,000 sharesNon-executive strike:$23.05 per shareOption term:10-year term+5 more
8 metrics
Non-executive options74,000 sharesNon-qualified stock options granted March 24, 2026 to four non-executive hires
Non-executive strike$23.05 per shareExercise price for 74,000 non-executive stock options
Option term10-year termTerm of non-qualified stock options granted under inducement plan
CEO RSUs500,000 RSUsRestricted stock units granted to CEO Jennifer Jarrett on March 30, 2026
CEO options1,500,000 sharesNon-qualified stock options granted to CEO on March 30, 2026
CEO option strike$25.50 per shareExercise price of CEO non-qualified stock options
Option vesting25% after 1 yearOptions vest 25% on first anniversary, then monthly over 36 months
RSU vesting4-year scheduleRSUs vest annually over four years
Market Reality Check
Price:$24.27Vol:Volume 171,710 is 49% bel...
low vol
$24.27Last Close
VolumeVolume 171,710 is 49% below the 20-day average of 338,007.low
TechnicalPrice at $25.50, trading above 200-day MA at $23.94 and 12.73% below 52-week high of $29.22.
Peers on Argus
No peers from the Biotechnology group appeared in the momentum scanner; current ...
No peers from the Biotechnology group appeared in the momentum scanner; current pricing around $25.50 with a -0.51% move looks stock-specific rather than sector-driven.
Full-year 2025 loss driven by acquired in-process R&D charge.
Pattern Detected
Recent news has shown directionally aligned reactions: positive leadership changes saw a sharp gain, while financially heavy results coincided with a decline.
Recent Company History
Over recent weeks, Damora reported 2025 results highlighting about $535 million in cash, R&D expense of $26.9M, G&A of $9.7M, and a net loss of $209.8M. Shortly after, the company announced Jennifer Jarrett’s appointment as President and CEO effective March 30, 2026, which was followed by a 27.07% move higher. Today’s inducement grants formalize equity incentives tied to those recent leadership hires.
Market Pulse Summary
This announcement details equity inducement grants to four new hires and the incoming CEO, including...
Analysis
This announcement details equity inducement grants to four new hires and the incoming CEO, including 1,500,000 options and 500,000 RSUs with multi-year vesting. It follows Damora’s recent CEO appointment and earlier disclosure of a $209.8M net loss alongside about $535M in cash. Investors may focus on how this refreshed leadership team advances lead program DMR-001 and manages expenses while these long-term incentives vest.
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement grantsfinancial
"The inducement grants were approved by Damora’s Board of Directors"
Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.
non-qualified stock optionsfinancial
"consist of non-qualified stock options to purchase an aggregate of 74,000 shares"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
restricted stock unitsfinancial
"she received a grant of 500,000 restricted stock units ("RSUs")"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
rsusfinancial
"she received a grant of 500,000 restricted stock units ("RSUs")"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
stock optionfinancial
"the terms and conditions of a stock option or RSU award agreement"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
AI-generated analysis. Not financial advice.
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora’s Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants made on March 24, 2026 to the non-executive employees consist of non-qualified stock options to purchase an aggregate of 74,000 shares of Damora’s common stock with a 10-year term and an exercise price of $23.05 per share. In connection with Ms. Jarrett’s appointment as President and Chief Executive Officer, on March 30, 2026, she received a grant of 500,000 restricted stock units ("RSUs") and non-qualified stock options to purchase 1,500,000 shares of Damora’s common stock at an exercise price of $25.50 per share. All of the options vest as to 25% on the first anniversary of the applicable grant date and in equal monthly installments for the following 36 months, and the RSUs vest annually over four years. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of a stock option or RSU award agreement.
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
What equity awards did Damora (DMRA) grant to new CEO Jennifer Jarrett on March 30, 2026?
She received 500,000 restricted stock units and options to buy 1,500,000 shares at $25.50 per share. According to Damora, these awards vest 25% after one year, then monthly or annually over the following vesting periods.
What inducement grants did Damora (DMRA) make to non-executive hires on March 24, 2026?
Damora granted non-qualified stock options to purchase an aggregate of 74,000 shares with a 10-year term at $23.05 per share. According to Damora, these awards were approved under Nasdaq Listing Rule 5635(c)(4).
How do the options and RSUs granted by Damora (DMRA) vest over time?
All options vest 25% on the first anniversary, then in equal monthly installments over 36 months; RSUs vest annually over four years. According to Damora, the awards follow the company’s 2022 Inducement Plan and award agreements.
Under what rule were Damora's (DMRA) inducement grants approved and why does that matter?
The grants were made as inducements under Nasdaq Listing Rule 5635(c)(4), allowing new-hire awards outside existing plans. According to Damora, the Board or independent Compensation Committee approved the awards consistent with that rule.
What are the exercise prices and term lengths for the options granted by Damora (DMRA)?
Non-executive hire options were priced at $23.05 with a 10-year term; the CEO options are priced at $25.50. According to Damora, both option sets are non-qualified stock options subject to award agreements.
